BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Effects of soy supplementation on gene expression in breast cancer

Dataset: Effects of soy supplementation on gene expression in breast cancer

Background There are conflicting reports on the impact of soy on breast carcinogenesis. This study examines the effects of soy...

Registered by ArrayExpress Uploader
View Dataset

Background There are conflicting reports on the impact of soy on breast carcinogenesis. This study examines the effects of soy supplementation on breast cancer-related genes and pathways. Methods Women (n = 140) with early-stage breast cancer were randomized to soy protein supplementation (n = 70) or placebo (n = 70) for 7 to 30 days, from diagnosis until surgery. Adherence was determined by plasma isoflavones: genistein and daidzein. Gene expression changes were evaluated by NanoString inin pre- and post-treatment tumor tissue. Genome-wide expression analysis was performed on post-treatment tissue. Proliferation (Ki67) and apoptosis (Cas3) were assessed by immunohistochemistry. Results Plasma isoflavones rose in the soy group (two-sided Wilcoxon rank-sum test, P < .001) and did not change in the placebo group. In paired analysis of pre- and post-treatment samples, 21 genes (out of 202) showed altered expression (two-sided Student’s t-test, P < .05). Several genes including FANCC and UGT2A1 revealed different magnitude and direction of expression changes between the two groups (two-sided Student’s t-test, P < .05). A high-genistein signature consisting of 126 differentially expressed genes was identified from microarray analysis of tumors. This signature was characterized by overexpression (>2 fold) of cell cycle transcripts, including those which promote cell proliferation, such as FGFR2, E2F5, BUB1, CCNB2, MYBL2, CDK1, and CDC20 (P < .01). Soy intake did not result in statistically significant changes in Ki67 or Cas3. Conclusions Gene expression associated with soy intake and high plasma genistein define a signature characterized by overexpression of FGFR2 and genes that drive cell cycle and proliferation pathways. These findings raise the concerns that in a subset of women soy could adversely affect gene expression in breast cancer. Genome-wide expression analysis was performed on breast cancer tissue from women following treatment with soy (n=28) or placebo (n=23).

Species:
human

Samples:
51

Source:
E-GEOD-58792

Updated:
Dec.12, 2014

Registered:
Jul.10, 2014


Factors: (via ArrayExpress)
Sample PREDICTED MOLECULAR SUBTYPE MENOPAUSAL STATUS PLASMA GENISTEIN NG/ML ER.STATUS TREATMENT
GSM1419673 LumA pre 1.5 P placebo
GSM1419672 LumB post 0 N placebo
GSM141967 LumB pre 46.9 P soy
GSM1419670 LumA pre 5.9 P soy
GSM1419669 LumA post 169 P soy
GSM1419668 basal pre 155 N soy
GSM1419667 LumA pre 38.3 P soy
GSM1419666 LumA pre 4.8 P soy
GSM1419665 LumA post 2.1 P placebo
GSM1419664 LumA pre 3.6 P placebo
GSM1419663 LumA post 9.7 P soy
GSM1419662 LumA pre 3.76 P soy
GSM141966 LumA pre 0.33 P placebo
GSM1419660 LumB post 0.36 P placebo
GSM1419659 LumB pre 0.61 P soy
GSM1419658 basal pre 0.36 N placebo
GSM1419657 LumA post 0.34 P placebo
GSM1419656 LumA pre 0.35 P soy
GSM1419655 LumA pre 0.34 P soy
GSM1419654 LumA pre 0.35 P placebo
GSM1419653 LumA post 0.53 P placebo
GSM1419652 LumB post 0.34 P soy
GSM141965 LumA pre 1.4 P soy
GSM1419650 LumB pre 27 P soy
GSM1419649 basal pre 84.5 N soy
GSM1419648 basal pre 0.33 N placebo
GSM1419647 basal post 0.34 N soy
GSM1419646 LumB post 110 P soy
GSM1419645 Her2 pre 0.34 N soy
GSM1419644 basal pre 0.33 N soy
GSM1419643 LumB pre 9.62 P soy
GSM1419642 LumB post 1.64 P placebo
GSM141964 LumA post 4.5 P placebo
GSM1419640 LumA post 1.45 P placebo
GSM1419639 basal post 1.12 N soy
GSM1419638 LumA post 1.86 P placebo
GSM1419637 Her2 post 37.01 N soy
GSM1419636 LumA pre 1.25 P placebo
GSM1419635 LumB post 93.3 P soy
GSM1419634 LumA post 1.93 P soy
GSM1419633 LumB post 201.02 P soy
GSM1419632 LumA post 2.47 P placebo
GSM141963 LumA pre 6.89 P placebo
GSM1419630 basal post 387.86 N soy
GSM1419629 LumA post 6.45 P placebo
GSM1419628 LumB post 3.31 P placebo
GSM1419627 LumB post 1.32 P placebo
GSM1419626 basal post 1.15 N soy
GSM1419625 LumA pre 1.29 P placebo
GSM1419624 LumB post 51.61 P soy
GSM1419623 LumB pre 6.26 P soy

Tags

  • breast
  • breast cancer
  • cancer
  • cell
  • genome
  • protein

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use